Comparison of IgG and Neutralizing Antibody Response After Pfizer BioNTech COVID-19 Vaccine Among Iraqi Individuals

Q4 Biochemistry, Genetics and Molecular Biology Journal of Biomolecular Techniques Pub Date : 2023-06-27 DOI:10.51173/jt.v5i2.1267

Najat Saeed Hussein, Izzat Abdulsatar Al-Rayahi, Salwa S. Muhsin, Redhwan Abdul Kareem Alameer

{"title":"Comparison of IgG and Neutralizing Antibody Response After Pfizer BioNTech COVID-19 Vaccine Among Iraqi Individuals","authors":"Najat Saeed Hussein, Izzat Abdulsatar Al-Rayahi, Salwa S. Muhsin, Redhwan Abdul Kareem Alameer","doi":"10.51173/jt.v5i2.1267","DOIUrl":null,"url":null,"abstract":"SARS-C0V-2 has quickly caused a pandemic. The distribution of vaccines is presently underway in an effort to stop the viral transmission and stop fatalities, several vaccinations have been created to decrease COVID virus disease, in 2019, the development of vaccine-induced population immunity is an important global strategy. Review of the anti-spike protein receptor-binding domain (S-RBD) a person's level of immune response to antibody strategy can be used to assess SARS-CoV-2 viral infection in 2019. Their efficacy, safety, and immunogenicity in various population are not thoroughly understood. The objective of this study was to evaluate the vaccinations adverse effects as well as determine the immunogenicity of the messenger ribonucleic acid (mRNA) BNT162b2 vaccines through the production of IgG and neutralizing antibodies against the protein s subunit. A total of 41 vaccinated individuals with Pfizer-BioNTech COVID-19 vaccine, as well as (10) non vaccinated were included in the study. Measurements of Neutralizing antibody (Nab) levels and CoV-IgG levels were tested by fluorescence Immunochromatographic assay. IgG and Nab levels showed a significant difference between its level in the sera of vaccinated and controls (p<0.05). This means the majority of immunization recipients between the ages of 18 -50 years can develop an immunological response to the SARS-Cov-2 vaccine.","PeriodicalId":39617,"journal":{"name":"Journal of Biomolecular Techniques","volume":"58 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomolecular Techniques","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51173/jt.v5i2.1267","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

Abstract

SARS-C0V-2 has quickly caused a pandemic. The distribution of vaccines is presently underway in an effort to stop the viral transmission and stop fatalities, several vaccinations have been created to decrease COVID virus disease, in 2019, the development of vaccine-induced population immunity is an important global strategy. Review of the anti-spike protein receptor-binding domain (S-RBD) a person's level of immune response to antibody strategy can be used to assess SARS-CoV-2 viral infection in 2019. Their efficacy, safety, and immunogenicity in various population are not thoroughly understood. The objective of this study was to evaluate the vaccinations adverse effects as well as determine the immunogenicity of the messenger ribonucleic acid (mRNA) BNT162b2 vaccines through the production of IgG and neutralizing antibodies against the protein s subunit. A total of 41 vaccinated individuals with Pfizer-BioNTech COVID-19 vaccine, as well as (10) non vaccinated were included in the study. Measurements of Neutralizing antibody (Nab) levels and CoV-IgG levels were tested by fluorescence Immunochromatographic assay. IgG and Nab levels showed a significant difference between its level in the sera of vaccinated and controls (p<0.05). This means the majority of immunization recipients between the ages of 18 -50 years can develop an immunological response to the SARS-Cov-2 vaccine.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊拉克人接种新冠病毒疫苗后IgG和中和抗体反应的比较

SARS-C0V-2迅速引起了大流行。目前正在分发疫苗，以阻止病毒传播和死亡，已经开发了几种疫苗以减少COVID - 19病毒病，2019年，开发疫苗诱导的人群免疫是一项重要的全球战略。回顾抗刺突蛋白受体结合域(S-RBD)一个人对抗体策略的免疫反应水平，可用于评估2019年SARS-CoV-2病毒感染。它们在不同人群中的有效性、安全性和免疫原性尚未完全了解。本研究的目的是通过产生针对mRNA的IgG和中和抗体来评估疫苗接种的不良反应，并确定其免疫原性。共有41名接种了辉瑞- biontech COVID-19疫苗的个体和10名未接种疫苗的个体被纳入研究。采用荧光免疫层析法检测中和抗体(Nab)和冠状病毒igg水平。免疫组与对照组血清IgG和Nab水平差异有统计学意义(p<0.05)。这意味着年龄在18 -50岁之间的大多数免疫接种者可以对SARS-Cov-2疫苗产生免疫反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Biomolecular Techniques Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： The Journal of Biomolecular Techniques is a peer-reviewed publication issued five times a year by the Association of Biomolecular Resource Facilities. The Journal was established to promote the central role biotechnology plays in contemporary research activities, to disseminate information among biomolecular resource facilities, and to communicate the biotechnology research conducted by the Association’s Research Groups and members, as well as other investigators.